The short version of purity testing fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-02 and is reviewed periodically as new material appears.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
| Property | Value | Notes |
|---|---|---|
| Form | Lyophilized powder or frozen solution | Powder is generally more stable for long-term storage. |
| Recommended storage | -20 °C, desiccated, protected from light | -80 °C for solutions or sensitive sequences. |
| Reconstitution solvent | Water, buffer, or organic co-solvent | Choice depends on peptide solubility and assay. |
| Freeze-thaw stability | Limited; avoid repeated cycles | Aliquoting into single-use portions reduces damage. |
| Contamination control | Aseptic technique and sterile filtration | Filters may adsorb peptides; validate recovery. |
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Temperature logs and cold-chain documentation help identify excursions that may compromise a batch. Automated freezers, desiccant packs, and sealed containers limit moisture and frost accumulation. Aliquoting small portions before freezing reduces the number of times the main stock changes temperature. Labels should include peptide name, lot, concentration if known, solvent, and date prepared. Periodic analytical verification by high-performance liquid chromatography or mass spectrometry can detect degradation, truncation, or sequence errors that visual inspection cannot reveal.
Practical handling begins with an inventory record that links each vial to a lot number, synthesis date, and purity certificate. Before opening a container, allow it to equilibrate to room temperature to prevent condensation on the powder. Weighing or transferring should occur in a low-humidity environment using tools that minimize static and adsorption. Hygroscopic peptides may gain water quickly, changing mass and concentration estimates. Recording the container's initial mass and any visible changes supports later reconciliation of material.
Reconstitution introduces additional variables: solvent choice, pH, ionic strength, and filtration. Many sequences dissolve readily in water, while hydrophobic ones may need acetonitrile, dimethyl sulfoxide, or a small amount of base. Adding solvent slowly and avoiding vigorous vortexing can reduce foaming and shear-induced aggregation. If the solution appears cloudy, filtration may remove particulates but can also remove aggregated peptide and alter concentration. A clear solution does not by itself confirm correct sequence or purity, so analytical checks remain necessary.
== Chemistry == Ketoconazole is a synthetic imidazole. It is a nonsteroidal compound. It is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole). Levoketoconazole is under development for potential clinical use as a steroidogenesis inhibitor with better tolerability and less toxicity than ketoconazole. Other steroidogenesis inhibitors besides ketoconazole and levoketoconazole include the nonsteroidal compound aminoglutethimide and the steroidal compound abiraterone acetate.
Also in 1992, the Dow Corning Corporation, a silicone products and breast implant manufacturer, announced the discontinuation of five implant-grade silicones, but would continue producing 45 other, medical-grade, silicone materials—three years later, in 1995, the Dow Corning Corporation went bankrupt when it faced large class action lawsuits claiming a variety of illnesses.
Stargirl and her team were briefly introduced in the Arrowverse crossover "Crisis on Infinite Earths" in January 2020, through archive footage from "The Justice Society" episode. Stargirl is set on a new Earth-2, created during the crossover. Stargirl from the pre-Crisis Earth-1 had previously appeared in three episodes of season two of Legends of Tomorrow, portrayed by Sarah Grey, between October 2016 and February 2017. Regarding any proper crossovers with the Arrowverse, Johns and Bassinger were keen on the idea. Johns said that "right now the main concern is making sure that this show is great, that these characters are great, that they have their own stories and they get the proper screen time and the proper episodes to develop on their own. So hopefully in the future we can do something fun, but the first season is all about making sure that Stargirl is the best show it can possibly be". Bassinger added that there had already been preliminary discussion about crossing over with The Flash, and she was hopeful to be able to crossover with Melissa Benoist on Supergirl. John Wesley Shipp reprised his role as an alternate version of Jay Garrick from The Flash. Johns said Shipp's appearance helped connect "our universe directly with the other shows, and also shows that were part of a grander universe. It opens up the door to opportunities for us to eventually interact with those Arrowverse characters, and that was important".
== Distribution and habitat == Blue gum grows in forests in New South Wales, Victoria and Tasmania, including some of the Bass Strait Islands. The nominate subspecies E. g. subsp. globulus is mainly found in lowland parts of Tasmania, but is also found on some Bass Strait islands including King Island, and in the extreme south-west of Victoria. Subspecies E. g. subsp. bicostata occurs in montane and tableland areas between the Carrai Plateau in northern New South Wales and the Pyrenees in Victoria. Subspecies E. g. subsp. maidenii occurs on near-coastal ranges of south-eastern New South Wales and eastern Victoria. Subspecies E. g. subsp. pseudoglobulus is mostly distributed in eastern Gippsland but there are isolated populations further inland and in the Nadgee Nature Reserve in south-eastern New South Wales.
Perchlorate compounds oxidize organic compounds, especially when the mixture is heated. The explosive decomposition of ammonium perchlorate is catalyzed by metals and heat. As perchlorate is a weak Lewis base (i.e., a weak electron pair donor) and a weak nucleophilic anion, it is also a very weakly coordinating anion. This is why it is often used as a supporting electrolyte to study the complexation and the chemical speciation of many cations in aqueous solution or in electroanalytical methods (voltammetry, electrophoresis…). Although the perchlorate reduction is thermodynamically favorable (∆G < 0; E° > 0), and that ClO−4 is expected to be a strong oxidant, most often in aqueous solution, it is practically an inert species behaving as an extremely slow oxidant because of severe kinetics limitations. The metastable character of perchlorate in the presence of reducing cations such as Fe2+ in solution is due to the difficulty to form an activated complex facilitating the electron transfer and the exchange of oxo groups in the opposite direction. These strongly hydrated cations cannot form a sufficiently stable coordination bridge with one of the four oxo groups of the perchlorate anion. Although thermodynamically a mild reductant, Fe2+ ion exhibits a stronger trend to remain coordinated by water molecules to form the corresponding hexa-aquo complex in solution. The high activation energy of the cation binding with perchlorate to form a transient inner sphere complex more favourable to electron transfer considerably hinders the redox reaction.
Sources: en.wikipedia.org
There was a large outbreak of eosinophilia-myalgia syndrome (EMS) in the U.S. in 1989, with more than 1,500 cases reported to the CDC and at least 37 deaths. After preliminary investigation revealed that the outbreak was linked to intake of tryptophan, the U.S. Food and Drug Administration (FDA) recalled tryptophan supplements in 1989 and banned most public sales in 1990, with other countries following suit. Subsequent studies suggested that EMS was linked to specific batches of L-tryptophan supplied by a single large Japanese manufacturer, Showa Denko. It eventually became clear that recent batches of Showa Denko's L-tryptophan were contaminated by trace impurities, which were subsequently thought to be responsible for the 1989 EMS outbreak. However, other evidence suggests that tryptophan itself may be a potentially major contributory factor in EMS. There are also claims that a precursor reached sufficient concentrations to form a toxic dimer. The FDA loosened its restrictions on sales and marketing of tryptophan in February 2001, but continued to limit the importation of tryptophan not intended for an exempted use until 2005. The fact that the Showa Denko facility used genetically engineered bacteria to produce the contaminated batches of L-tryptophan later found to have caused the outbreak of eosinophilia-myalgia syndrome has been cited as evidence of a need for "close monitoring of the chemical purity of biotechnology-derived products".
On the basis of favorable early results, ongoing research is examining proposed psychedelic therapies for conditions including major depressive disorder, and anxiety and depression linked to terminal illness. The United States Food and Drug Administration has granted breakthrough therapy status, which expedites the assessment of promising drug therapies for potential approval, to psilocybin therapy for treatment-resistant depression and major depressive disorder. It has been proposed that psychedelics used for therapeutic purposes may act as active "super placebos". On the other hand, the inverse placebo effect (or "knowcebo" effect) caused by blinding failure may create an illusion of large effect sizes with psychedelics.
In February 2013, the Australian Sports Anti-Doping Authority (ASADA) and the World Anti-Doping Agency (WADA) began an investigation into the legality of Essendon's supplements program during the 2012 AFL season and the preceding preseason. Thirty-four Essendon players—including Watson—were suspected of taking the banned peptide Thymosin beta-4. This quickly led to debate over whether or not a guilty verdict would see Watson stripped of the medal. The investigation and court action stretched over the following four years. Initially, the AFL Tribunal delivered a not guilty verdict in March 2015, but on appeal in the Court of Arbitration for Sport (CAS), the players were found guilty in January 2016, resulting in the suspensions of all thirty-four players. An appeal lodged against that decision in the Federal Supreme Court of Switzerland was dismissed in October 2016. Following the guilty verdict handed down by the CAS in January, it was announced the AFL Commission would meet in February to determine whether Watson would retain his Brownlow Medal; however, this decision was delayed until the outcome of the Federal Supreme Court appeal. The final decision regarding Jobe Watson's Brownlow medal win was decided by the AFL Commission in late November 2016, with Watson retrospectively ruled ineligible for the award, and the medal then awarded to the next highest vote-getters, Cotchin and Mitchell, under the normal rules regarding ineligible players; Watson had pre-empted the decision by announcing on 11 November 2016 that he would hand back the medal.
==== Acetaminophen ==== One of the main types of drug studies conducted is using astronauts as test subjects and measuring drug dynamics before and after spacecraft flight. A study on acetaminophen pharmacokinetics was performed on ten astronauts, studying its concentration dynamics in saliva two months before spaceflight and during long-term spaceflight. Saliva samples were analyzed at intervals of 0.017, 0.33, 0.5, 0.75, 1, 2, 4, and 6 hours after acetaminophen intake by HPLC with UV spectrophotometric detection at 254 nm. The absorption of acetaminophen during spaceflight was delayed after tablet administration and the bioavailability of the encapsulated drug was found to be moderately decreased. Additionally, the half-life of encapsulated acetaminophen was prolonged during spaceflight.
EMPA is employed in monazite geochronology especially for in-situ chemical dating (total-Pb dating). The high content of U, Th and Pb in monazite match with the requirement arising from the relatively higher lower detection limit. Therefore, EMPA is a high-resolution (approximately 1 μm), rapid and inexpensive method in chemical dating to resolve growth histories of monazite. It can achieve a precision of 5–10 myr in Pb-rich monazite, and 10–20 myr in Pb-poor monazite.
Sources: en.wikipedia.org
No. Allowing the sealed vial to equilibrate to room temperature reduces condensation on the powder. Condensation can introduce moisture and promote degradation. Equilibration usually takes 15 to 30 minutes depending on vial size.
Aliquoting limits repeated freeze-thaw cycles that can cause aggregation or loss. Single-use portions reduce contamination risk and handling variability. It also allows separate testing without disturbing the main stock.
Inspect packaging, temperature indicators, and vial condition before storage. Record any deviations from the expected temperature range. If a deviation occurred, analytical testing may be warranted before use.
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.